PL3178481T3 - Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji - Google Patents

Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji

Info

Publication number
PL3178481T3
PL3178481T3 PL16203579T PL16203579T PL3178481T3 PL 3178481 T3 PL3178481 T3 PL 3178481T3 PL 16203579 T PL16203579 T PL 16203579T PL 16203579 T PL16203579 T PL 16203579T PL 3178481 T3 PL3178481 T3 PL 3178481T3
Authority
PL
Poland
Prior art keywords
production method
high density
density lipoprotein
reconstituted high
lipoprotein formulation
Prior art date
Application number
PL16203579T
Other languages
English (en)
Inventor
Samuel Wright
Martin Imboden
Reinhard Franz Bolli
Marcel Waelchli
Original Assignee
Csl Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Limited filed Critical Csl Limited
Publication of PL3178481T3 publication Critical patent/PL3178481T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16203579T 2010-06-30 2011-06-30 Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji PL3178481T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35992510P 2010-06-30 2010-06-30
EP16203579.4A EP3178481B1 (en) 2010-06-30 2011-06-30 A reconstituted high density lipoprotein formulation and production method thereof
EP11799979.7A EP2588113B1 (en) 2010-06-30 2011-06-30 A reconstituted high density lipoprotein formulation and production method thereof
PCT/AU2011/000819 WO2012000048A1 (en) 2010-06-30 2011-06-30 A reconstituted high density lipoprotein formulation and production method thereof

Publications (1)

Publication Number Publication Date
PL3178481T3 true PL3178481T3 (pl) 2019-07-31

Family

ID=45401226

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11799979T PL2588113T3 (pl) 2010-06-30 2011-06-30 Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji
PL16203579T PL3178481T3 (pl) 2010-06-30 2011-06-30 Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11799979T PL2588113T3 (pl) 2010-06-30 2011-06-30 Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji

Country Status (17)

Country Link
US (5) US8999920B2 (pl)
EP (3) EP3178481B1 (pl)
JP (2) JP5989641B2 (pl)
KR (1) KR101782309B1 (pl)
CN (2) CN103118683B (pl)
AU (1) AU2011274238B2 (pl)
CA (1) CA2803031C (pl)
DK (2) DK3178481T3 (pl)
ES (2) ES2617977T3 (pl)
HU (2) HUE042391T2 (pl)
IL (1) IL223815A (pl)
MX (1) MX2012014928A (pl)
PL (2) PL2588113T3 (pl)
SG (1) SG186386A1 (pl)
TR (1) TR201903209T4 (pl)
TW (1) TWI531388B (pl)
WO (1) WO2012000048A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617977T3 (es) * 2010-06-30 2017-06-20 Csl Limited Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
CN103833840A (zh) * 2012-11-27 2014-06-04 上海复星医药(集团)股份有限公司 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法
HK1220210A1 (zh) * 2013-06-05 2017-04-28 Csl Limited 制备载脂蛋白a-i (apo a-i)的方法
NZ631126A (en) 2013-08-08 2018-06-29 Csl Ltd Contaminant removal method
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
KR101563403B1 (ko) * 2013-11-05 2015-10-26 영남대학교 산학협력단 지방물질의 안전성 평가방법
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
JP6818264B2 (ja) * 2014-12-25 2021-01-20 国立大学法人京都大学 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
US20200038481A1 (en) * 2016-11-10 2020-02-06 Csl Limited Reconstituted high density lipoprotein treatment of myocardial infarction
JP2021501793A (ja) * 2017-11-07 2021-01-21 アルファコア ファーマ リミテッド ライアビリティ カンパニーAlphacore Pharma Llc 心疾患、心血管疾患及び関連する病状と症状を治療し保護する方法
AU2018396009A1 (en) * 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用
KR102531293B1 (ko) * 2021-12-06 2023-05-16 (주) 멥스젠 신규한 재구축 고밀도 지단백 나노입자

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
PL372925A1 (pl) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Zapobieganie i leczenie nawrotu zwężenia na drodze miejscowego podawania leku
BR0310100A (pt) 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
JP2006507223A (ja) 2002-05-17 2006-03-02 エスペリオン セラピューティクス,インコーポレイテッド 脂質代謝異常疾患の治療方法
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
US20070254832A1 (en) 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
CN100586958C (zh) * 2006-12-20 2010-02-03 上海莱士血液制品股份有限公司 高纯度载脂蛋白a-i的制备方法
KR100992488B1 (ko) 2006-12-29 2010-11-05 주식회사 녹십자 ApoA-I의 정제방법 및 정제된ApoA-I을 이용한재구축 HDL의 생산 방법
CA2694854C (en) 2007-08-17 2016-09-27 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
US8734853B2 (en) * 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
ES2617977T3 (es) 2010-06-30 2017-06-20 Csl Limited Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation

Also Published As

Publication number Publication date
AU2011274238A1 (en) 2013-01-17
EP2588113B1 (en) 2016-12-14
US9439946B2 (en) 2016-09-13
TWI531388B (zh) 2016-05-01
ES2718234T3 (es) 2019-06-28
SG186386A1 (en) 2013-01-30
CN105396122A (zh) 2016-03-16
US8999920B2 (en) 2015-04-07
EP3178481A1 (en) 2017-06-14
JP5989641B2 (ja) 2016-09-07
EP3492085A1 (en) 2019-06-05
US20170196935A1 (en) 2017-07-13
CN103118683B (zh) 2015-08-19
DK2588113T3 (en) 2017-03-20
DK3178481T3 (en) 2019-04-08
EP2588113A4 (en) 2014-12-03
US10335457B2 (en) 2019-07-02
WO2012000048A1 (en) 2012-01-05
HUE042391T2 (hu) 2019-06-28
TR201903209T4 (tr) 2019-03-21
CN103118683A (zh) 2013-05-22
KR101782309B1 (ko) 2017-09-27
US20130190226A1 (en) 2013-07-25
EP3178481B1 (en) 2019-01-02
CA2803031C (en) 2021-06-22
TW201206446A (en) 2012-02-16
CN105396122B (zh) 2020-09-11
KR20130100970A (ko) 2013-09-12
US20200171126A1 (en) 2020-06-04
US20160022768A1 (en) 2016-01-28
MX2012014928A (es) 2013-03-22
EP2588113A1 (en) 2013-05-08
JP2013529648A (ja) 2013-07-22
US20220133852A1 (en) 2022-05-05
PL2588113T3 (pl) 2017-06-30
IL223815A (en) 2017-08-31
ES2617977T3 (es) 2017-06-20
CA2803031A1 (en) 2012-01-05
US11058747B2 (en) 2021-07-13
JP2016188226A (ja) 2016-11-04
HUE032560T2 (en) 2017-09-28
AU2011274238B2 (en) 2013-09-26
US11723953B2 (en) 2023-08-15

Similar Documents

Publication Publication Date Title
HUE042391T2 (hu) Visszaoldott nagysûrûségû lipoprotein kiszerelés és elõállítási eljárása
ZA201401526B (en) Method and formulation for inhalation
GB201107863D0 (en) Method and product
EP2585656A4 (en) MODULAR MANUFACTURING SYSTEM AND METHOD THEREFOR
ZA201207262B (en) Smoking article,method of manufacturing such a smoking article and corresponding apparatus
EP2657188A4 (en) FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME
PL2539259T3 (pl) Maszyna przewijająca oraz sposób przewijania
PL2729377T3 (pl) Opakowanie zbiorcze i sposób wytwarzania takiego opakowania zbiorczego
GB201000688D0 (en) Product and method
ZA201207115B (en) Apparatus and method for manufacturing products
EP2589815A4 (en) DRIVE AND METHOD FOR THE PRODUCTION THEREOF
ZA201208316B (en) Method for manufacturing smoking articles and smoking articles
ZA201204641B (en) Method for preparing and detoxifying
GB201118985D0 (en) Product and method
GB201113610D0 (en) Product and method
SG10201604976RA (en) Hydroxy-aminopolymers and method for producing same
GB2491265B (en) Management apparatus and method thereof
SG11201400909WA (en) Composition and method for producing same
EP2698159A4 (en) PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF
GB201018467D0 (en) A machine and method of manufacturing a machine
HUP1100236A2 (en) Method for producing form pieces
SG10201509740PA (en) Picking and shipping method
PL2457714T3 (pl) Sposób wytwarzania materiałów włóknistych i ich produktów pochodnych
EP2570256A4 (en) MICROCENTLATE LAMINATE AND METHOD OF MANUFACTURING THEREOF
GB201107931D0 (en) Manufacturing method and product